Irritable bowel syndrome: A management strategy

Bailliere's Best Practice in Clinical Gastroenterology

Volumn 13, Issue 3, 1999, Pages 453-460

  Thompson, W Grant ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

IBS; Irritable bowel syndrome; Management; Management strategy; Treatment

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; ISPAGULA; LACTULOSE; LOPERAMIDE; METHYLCELLULOSE; POLYCARBOPHIL CALCIUM; SORBITOL; TRICYCLIC ANTIDEPRESSANT AGENT;

DIET; DOCTOR PATIENT RELATION; HUMAN; IRRITABLE COLON; REVIEW; SOCIAL PSYCHOLOGY;

EID: 0033213617     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0039     Document Type: Article

References (60)

1. Bommelaer G, Rouch M, Dapoigny M et al. Epidemiologie des troubles fonctionnels dans une population apparement saine. Gastroenterologie Clinique Et Biologique 1986; 10: 7-12.
2. Drossman DA, Li Z, Andruzzi E et al. U.S. Householder survey of functional gastrointestinal disorders: Prevalence, sociodemography and health impact. Digestive Diseases and Sciences 1993; 38: 1569- 1580.
3. Drossman DA, Sandler RS, McKee DC & Lovitz AJ. Bowel patterns amongst subjects not seeking health care. Gastroenterology 1982; 83: 529-534.
4. Heaton KW, O'Donnell LJD, Braddon FEM et al. Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters. Gastroenterology 1992; 102: 1962-1967 .
5. Talley NJ, Zinsmeister AR, Van Dyke C & Melton LJ III. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 927-934 .
6. Thompson WG & Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980; 79: 283-288.
7. Welch GW & Pomare EW. Functional gastrointestinal symptoms in a Wellington community sample. New Zealand Medical Journal 1990; 103: 418-420.
8. Whitehead WE, Winget C, Fedoravicius AS et al. Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer. Digestive Diseases and Sciences 1982; 27: 202-208.
9. Agreus L, Svardsudd K, Nyren O & Tibblin G. Irritable bowel syndrome and dyspepsia in the population: Overlap and lack of stability over time. Gastroenterology 1995; 109: 671 -680.
10. Talley NJ, Weaver AL, Zinsmeister AR & Melton LJ. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. American Journal of Epidemiology 1992; 136: 165-177.
11. Thompson WG, Heaton KW, Smyth GT & Smyth C. Irritable bowel syndrome in general practice. Gastroenterology 1997; 112: A837 .
12. Harvey RF, Mauad EC & Brown AM. Prognosis in the irritable bowel syndrome: A five-year prospective study. Lancet 1987; i: 963-965.
13. Holmes KM & Salter RH. Irritable bowel syndrome - A safe diagnosis. British Medical Journal 1982; 285: 1533-1534.
14. Svendsen JH, Munck LK & Andersen JR. Irritable bowel syndrome: Prognosis and diagnostic safety. A 5-year follow up study. Scandinavian Journal of Gastroenterology 1985; 20: 415-418.
15. Talley NJ, Gabriel SE, Harmsen WS et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-1741.
16. Thompson WG, Heaton KW, Smyth GT & Smyth C. Irritable bowel syndrome: The view from general practice. European Journal of Gastroenterology and Hepatology 1997; 9: 689-692.
17. Camilleri M, Thompson WG, Fleshman JW & Pemberton JH. Clinical management of intractable constipation. Annals of Internal Medicine 1996; 121: 520-528.
18. Guthrie E, Creed F, Dawson D & Tomenson B. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. British Journal of Psychiatry 1993; 163: 315-321.
19. Drossman DA & Thompson WG. Irritable bowel syndrome: A graduated, multicomponent treatment approach. Annals of Internal Medicine 1992; 116: 1009-1016.
20. Thompson WG. Gut Reactions. New York: Plenum Press, 1989.
21. Thompson WG. The irritable bowel syndrome: Pathogenesis and management. Lancet 1993; 341: 1569-1572.
22. Thompson WG, Creed FH, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gastroenterology International 1992; 5: 75-91.
23. Klein KB. Controlled treatment trials in the irritable bowel syndrome: A critique. Gastroenterology 1988; 95: 232-241.
24. Talley NJ, Owen BK, Boyce P & Paterson K. Psychological treatments for irritable bowel syndrome: A critique of controlled clinical trials. American Journal of Gastroenterology 1996; 91: 277-286.
25. Manning AP, Thompson WG, Heaton KW & Morris AF. Towards positive diagnosis of the irritable bowel. British Medical Journal 1978; 2: 653-654.
26. Drossman DA, Richter J, Talley NJ et al. Functional Gastrointestinal Disorders. Boston: Little Brown & Co, 1994.
27. Kruis W, Thieme CH, Weinzierl M et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7.
28. Blanchard EB, Scharff L, Schwarz SP et al. The role of anxiety and depression in the irritable bowel syndrome. Behaviour Research and Therapy 1990; 28: 401-405.
29. Creed F. Life events and appendectomy. Lancet 1981; i: 1381-1385.
30. Lydiard RB, Laraia MT, Howell EF & Ballenger JC. Can panic disorder present as irritable bowel syndrome. Journal of Clinical Psychiatry 1986; 47: 470-473.
31. Craig TK & Brown GW. Goal frustration and life event stress in the aetiology of painful gastrointestinal disorder. Journal of Psychosomatic Research 1984; 28: 411-421.
32. Drossman DA, Leserman J, Nachman G et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Annals of Internal Medicine 1990; 113: 828-833.
33. Lucey MR, Clark ML, Lowndes JO & Dawson AM. Is bran efficaceous in irritable bowel syndrome? A double blind placebo controlled study. Gut 1987; 28: 221-225.
34. Prior A & Whorwell PJ. Double blind study of isbagula in irritable bowel syndrome. Gut 1987; 28: 1510-1513.
35. Francis CY & Whorwell PJ. Bran and irritable bowel syndrome: Time for reappraisal. Lancet 1994; 344: 39-40.
36. Thompson WG. Doubts about bran. Lancet 1994; 344: 3.
37. Rumessen JJ & Goodman-Hayer J. Functional bowel disease, malabsorption and abdominal distress after ingestion of fructose, sorbitol and fructose sorbitol mixture. Gastroenterology 1988; 95: 694-700.
38. Suarez FL, Savaiano DA & Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. New England Journal of Medicine 1995; 333: 1-4.
39. Mayer EA. In Mayer EA & Raybould HE (eds) Basic and Clinical Aspects of Chronic Abdominal Pain, pp 3-28. New York: Elsevier, 1993.
40. Mayer EA. The sensitive and reactive gut. European Journal of Gastroenterology and Hepatology 1994; 6: 470-477.
41. Prior A, Sorial E, Sun W-M & Read NW. Irritable bowel syndrome: Differences between patients who show rectal sensitivity and those who do not. European Journal of Gastroenterology and Hepatology 1993; 5: 343-349.
42. Talley NJ, Nyren O, Drossman DA et al. The irritable bowel synrome: Toward optimal design of controlled treatment trials. Gastroenterology International 1994; 6: 189-211.
43. Luttecke K. A trial of trimebutine in spastic colon. Journal of Internal Medical Research 1978; 6: 86-88.
44. Mathias JR, Ferguson KL & Clench MH. Debilitating 'functional' bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog. Digestive Diseases and Sciences 1989; 34: 761-766.
45. Moshal MG & Herron M. A clinical trial of trimebutine in spastic colon. Journal of Internal Medical Research 1979; 7: 231-234.
46. Camilleri M & Choi M-G. Irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1997; II: 3-15 (Review).
47. Goulston K. Drug usage in the irritable colon syndrome. Medical Journal of Australia 1972; I: 1126-1131.
48. Ivey KJ. Are anticholinergics of use in the irritable bowel syndrome? Gastroenterology 1975; 68: 1300-1307.
49. Dew MJ, Evans BK & Rhodes J. Peppermint oil for the irritable bowel syndrome: A multicentre trial. British Journal of Clinical Practice 1984; 38: 394-398.
50. Nash P, Gould SR & Bernardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. British Journal of Clinical Practice 1986; 40: 292-293.
51. Passaretti S, Guslandi M, Imbimbo BP et al. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1989; 3: 267-276.
52. Tasman-Jones C. Mebeverine in patients with the irritable colon syndrome: Double blind study. New Zealand Medical Journal 1973; I: 232-235.
53. Evans PR, Bak YT, Kellow JE et al. Mebeverine alters small bowel motility in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1996; 10: 787-793.
54. Pace F, Coremans G, Dapoigny M et al. Therapy of irritable bowel syndrome - An overview. Digestion 1995; 56: 433-442.
55. Poynard T, Naveau S, Mory B & Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 1994; 8: 499-510.
56. Oddsson E, Rask-Madsen J, Krag E et al. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scandinavian Journal of Gastroenterology 1978; 13: 409-416.
57. Krevsky B, Maurer AH, Niewiarowski T & Cohen S. Effect of verapamil on human intestinal transit. Digestive Diseases and Sciences 1992; 37: 919-924.
58. van Dulman AM, Fennis JF & Bleijenberg G. Cognitive-behavioural group therapy for irritable bowel syndrome: Effects and long-term follow-up. Psychosomatic Medicine 1996; 58: 508-514 (Generic).
59. Whorwell PJ, Prior A & Colgan SM. Hypnotherapy in severe irritable bowel syndrome: Further experience. Gut 1987; 28: 423-425.
60. * Blanchard EB, Greene B, Scharff L & Schwarz-McMorrisorris SP. Relaxation training as treatment for irritable bowel syndrome. Biofeed and Self-regulation 1993; 3: 125-132.